- The Cooper Companies delivered a fourth-quarter record revenue of $1.065 billion, up 4.6% YoY and 3.4% organically, underpinned by strong performance from CooperVision (CV I) and CooperSurgical (CSI). Consolidated EPS on a non-GAAP basis rose 11% to $1.15, supported by ongoing operating discipline and a $150 million free cash flow generation in Q4.
- The quarter highlighted MiSight’s continued momentum (37% YoY), robust MyDay progression, and a strategic shift toward higher-margin premium lenses, aided by a robust private-label contracting cycle in both CVI and CSI. China weakness persisted (−28% in Q4) amid broader APAC softness, though the Americas and EMEA remained resilient; Asia Pacific activity remains a focal point for near-term improvement.
- Management outlined three core priorities: (1) sustained market share gains for CooperVision via the MyDay ecosystem and private-label expansion; (2) continued earnings growth and free cash flow generation, including $2.2B+ FCF target for 2026–2028 and a reorganization-driven annual pretax savings of about $50M starting in fiscal 2026; (3) capital return discipline with a continued emphasis on share repurchases and debt reduction. A formal strategic review was announced to explore value-creating opportunities, with Colleen Jay transitioning to the chair role and total shareholder return (TSR) added to executive compensation.
- Looking ahead, management provided 2026 guidance of roughly $4.30–$4.34 billion in revenue, non-GAAP EPS of $4.45–$4.60, and free cash flow of $575–$625 million, with CapEx compressing as the MyDay investment cycle winds down. For CVI and CSI, the year is expected to reflect mid‑single-digit organic growth in CVI and 4%–5% in CSI, with total 2026 organic growth guidance of 4.5%–5.5% for the group. The longer-term outlook contemplates continued leverage improvement, higher opex efficiency via AI-enabled operations, and a normalization of CapEx toward ~5% of revenue by 2027.